Loading...

Jason Limberis, PhD

Title(s)Postdoctoral Scholar, Medicine
SchoolSchool of Medicine
Phone628-206-8101
Emailjason.limberis@ucsf.edu
ORCID ORCID Icon0000-0002-7893-8416 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stellenbosch University, South AfricaBSc Molecular Biology with Biotechnology
    Stellenbosch University, South AfricaBSc HonsMolecular Biology
    University of Cape Town, South AfricaPhDMedicine
    The Centre for Genomic Regulation, SpainInternshipBioinformatics

    Collapse Overview 
    Collapse Overview
    My research focusses on the causative agent of tuberculosis, Mycobacterium tuberculosis: I apply a combination of wet work and bioinformatics to investigate genomic and transcriptional associates of drug resistance, clinical outcomes, and patient infectiousness. See www.SemiQuant.com for more information.

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Olayanju O, Esmail A, Limberis J, Dheda K. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis. Eur Respir J. 2019 Oct 16. PMID: 31619478.
      View in: PubMed
    2. Meldau R, Randall P, Pooran A, Limberis J, Makambwa E, Dhansay M, Esmail A, Dheda K. Same-Day Tools, Including Xpert Ultra and IRISA-TB, for Rapid Diagnosis of Pleural Tuberculosis: a Prospective Observational Study. J Clin Microbiol. 2019 Sep; 57(9). PMID: 31270183.
      View in: PubMed
    3. Olayanju O, Esmail A, Limberis J, Gina P, Dheda K. Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. Int J Infect Dis. 2019 Aug; 85:74-79. PMID: 31100421.
      View in: PubMed
    4. Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, Fadul M, Warren R, Dheda K. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018 05; 51(5). PMID: 29700106.
      View in: PubMed
    5. Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med. 2017 04; 5(4):269-281. PMID: 28109869.
      View in: PubMed
    6. Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, Chanda D, Esmail A, Peter J, Dheda K. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results? Clin Infect Dis. 2016 Apr 15; 62(8):995-1001. PMID: 26908793.
      View in: PubMed